Mecasermin

Mecasermin is a synthetic form of human insulin-like growth factor-1 (IGF-1), produced using recombinant DNA technology. It is primarily prescribed for treating severe primary IGF-1 deficiency (Primary IGFD), where patients have normal or elevated levels of growth hormone but insufficient IGF-1 production. The USA FDA approved Mecasermin in 2005 under the brand name Increlex. In October 2006, Tercica licensed the European rights for Increlex to the specialty pharmaceutical firm Ipsen, which received approval to market it in the European Union by August 2007. Mecasermin promotes growth by increasing the uptake of amino acids, glucose, and fatty acids, though it lowers blood sugar levels so effectively that high doses can cause severe hypoglycemia.Moreover, its capability to boost the absorption of fatty acids might result in lipogenesis or a rise, in storing body fat. This particular substance intrigues bodybuilders and athletes due, to its ability to improve the development of muscle and connective tissue potentially.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.